Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
about
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyPharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesPharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIVDrug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Clinical Pharmacokinetics of Ombitasvir.Clinical Pharmacokinetics of Paritaprevir.Clinical Pharmacokinetics of Dasabuvir.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration.Predicting drug interactions in addiction treatment.
P2860
Q31168033-FF7B0C23-2D96-455D-A405-4076EE180B91Q34680467-CA993696-8CB8-40D5-8510-6DA3C510B27AQ36445132-3424E0BB-902D-4E29-BA78-18F9A78EE63CQ37055231-2694B748-FEC8-402B-A4CA-D8814EFD135EQ37067118-B7EF87F0-C7B9-4826-A2CD-B03247D5EE6EQ38621245-746C4A5F-EB1D-46D6-AE63-A9DEC7FD14DFQ38893128-9B5A4937-7A08-4A2F-97A3-B46BF56655E6Q38929010-1BD52B6A-3F1A-43A5-ADF0-5CB0F5ABBB92Q39147495-1A2EA7A9-EE3E-4297-9A52-8375EE703838Q39150134-F5C16B23-EC90-434B-A799-61A974E22F34Q39160612-5E56DCF0-521C-4C46-9184-354154B1019FQ39357557-0B2922A2-196E-4066-8CDD-0B46901C7787Q40597366-FF79C247-C0A4-405E-A759-82E99EC92D5BQ40842140-9C32394B-F02C-435A-8601-FA673471DEE2Q45894857-723E34E6-1975-43AB-891C-610952851D66Q47752166-49DBCA91-9D15-4D72-BC71-5F20DC31ACA1
P2860
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@ast
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@en
type
label
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@ast
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@en
prefLabel
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@ast
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@en
P2093
P2860
P356
P1476
Drug Interactions with the Dir ...... vir and Paritaprevir-Ritonavir
@en
P2093
Akshanth R Polepally
Amit Khatri
Haoyu Wang
Jiuhong Zha
Prajakta S Badri
Rajeev M Menon
Sandeep Dutta
Thomas J Podsadecki
Walid M Awni
Yi-Lin Chiu
P2860
P304
P356
10.1128/AAC.01778-15
P407
P577
2015-10-12T00:00:00Z